THE GLOBAL FUND

Results Report

2024

Results Report 2024: A Suite of Booklets

Embargoed until 19 September



Summary and Key Results

Standalone chapters:

HIV: State of the Fight

Tuberculosis: State of the Fight

Malaria: State of the Fight

Health and Community Systems

Colliding Crises

Investing for Impact

THE GLOBAL FUND



2024 Results Reports

Key results for 2023



25 million

people on **antiretroviral therapy for HIV** in 2023.

7.1 million

people **treated for tuberculosis** in 2023.

227 million

mosquito nets distributed to fight malaria in 2023.

© The Global Fund/Vincent Becker

Headline Messages (1/4)

Since 2002, the Global Fund partnership has saved **65 million lives**.

2023 was a year of significant progress in the fight against HIV, tuberculosis (TB) and malaria. In countries where the Global Fund invests, the response to HIV, TB and malaria has fully recovered from the disruptions in service delivery caused by COVID-19.

In 2023, we invested US$1.8 billion – the highest amount ever in a single calendar year – to strengthen health and community systems. Between 2024-2026, we are investing approximately US$6 billion* in health and community systems to support countries to deliver better health outcomes across all diseases, build pandemic preparedness, and work towards achieving universal health coverage.

*This figure is based on the recently endorsed Global Fund Strategy Committee methodology that integrates direct investments in resilient and sustainable systems for health (RSSH) and contributions to RSSH through investments in the fight against HIV, TB and malaria (contributory RSSH). The amount is derived from approved and signed grant budgets and RSSH-related catalytic investments. This methodology excludes Global Fund Secretariat operating expenses.

Headline Messages
(2/4)

Besides our direct investments in health and community systems, **our funding in the fight against HIV, TB and malaria has freed up resources and capacities**, making health and community systems better able to respond to other diseases.

Our investments in HIV up to the end of 2023 have freed up 1.66 billion HIV-related hospitalization days and averted 1.36 billion outpatient visits, which generated US$85 billion in cost savings.

Global Fund investments have consistently delivered an extraordinarily high return. Our disbursements of US$63 billion between 2002 and 2023 are estimated to have generated health gains with a monetized intrinsic value of US$1.2 trillion and direct productivity gains of US$400 billion.

The Global Fund/Johis Alarcón/Panos

The Global Fund/Evgeny Maloletka

Headline Messages
(3/4)

In 2023, our market-shaping efforts resulted in significant price reductions for key commodities across HIV, TB and malaria, enabling governments to expand interventions and invest in other critical areas. Working with partners, we were able to reduce prices by 25% for the preferred first-line HIV treatment, by 20% for diagnostic test cartridges for TB, by 30% for the short course TB preventive treatment known as 3HP, and by 55% for bedaquiline, the main treatment for drug-resistant TB. We also secured new dual active ingredient insecticide-treated nets, which are more effective against insecticide-resistant mosquitoes than conventional ones, at a comparable price.

Headline Messages
(4/4)

In 2023, the world was again hit by multiple crises, including climate change, conflict, the anti-gender and anti-rights movements and attacks on civil society. **The Global Fund partnership acted with agility to support countries to confront these challenges and continue their lifesaving work, strengthening health and community systems, providing emergency funds and partnering with humanitarian organizations to support people affected by crises.**

Working hand in hand with governments, communities, the private sector, civil society and our technical partners, and with people affected by the diseases at the center of the response, **we can end AIDS, TB and malaria as public health threats, accelerate progress towards UHC and deliver on the SDG 3 ambition of health and well-being for all**.

The Global Fund/Brian Otieno

The Global Fund/Brian Otieno

HIV

State of the Fight

In 2023, Global Fund-supported HIV programs prioritized high-impact interventions for people with the greatest need for prevention, testing and treatment. However, to end the disease by 2030, we must significantly scale up investment, strengthen political will and tackle human rights and gender-related barriers to health.

HIV: State of the Fight

Trends in HIV and AIDS

Trends in AIDS-related deaths

In countries where the Global Fund invests



Trends in new HIV infections

In countries where the Global Fund invests



HIV burden estimates from UNAIDS, 2024 release. Estimation of “no prevention or ARVs” trends from Goals Model, Asian Epidemic Model (AEM) and AIDS Impact Model (AIM).

HIV: State of the Fight

Key HIV results for 2023 in countries where we invest

25 million People on antiretroviral therapy for HIV*

People living with HIV who know their status



People living with HIV receiving ARVs



People living with HIV with suppressed viral load



*Programmatic results achieved during 2022 by countries and regions where the Global Fund invests. Progress graphs are based on latest published data from WHO (2022 release for TB and malaria) and UNAIDS (2023 release). Malaria mosquito net coverage calculated based on 38 African countries for which data is available from WHO/Malaria Atlas Project estimates.

Key Results

HIV: State of the Fight

In countries where the Global Fund invests:

25M

People were on **antiretroviral therapy for HIV** in 2023, up from 17.5 million in 2017. Coverage increased from 22% in 2010 to 78% in 2023. Global target: 90% by 2025.

72%

Of people **living with HIV** had a suppressed viral load in 2023, up from 15% in 2015. Global target: 86% by 2025.

17.9M

People were **reached with HIV prevention services** in 2023, including 8 million people from key populations and 8.5 million young people.

53.8M

HIV tests were taken (including 13.1 million by priority and key populations). People living with HIV with knowledge of their status increased from 68% in 2015 to 84% in 2023. Global target: 95% by 2025.

695K

Mothers living with HIV received medicine to keep them alive and prevent transmitting HIV to their babies in 2023. Coverage increased from 49% in 2010 to 84% in 2023. Global target: 100% by 2025.

925K

Voluntary medical male circumcisions were conducted for HIV prevention in 2023.

322K

People **initiated oral antiretroviral pre-exposure prophylaxis (PrEP)** in 2023.

HIV: State of the Fight

Our progress

In countries where the Global Fund invests, AIDS-related deaths have declined by 73% since 2002 and new infections by 61%. The HIV mortality rate has reduced by 81% since 2002, and the incidence rate declined by 73%.

- Several Global Fund-supported countries are achieving significant milestones: **Botswana, Eswatini, Kenya, Malawi, Rwanda, Zambia** and **Zimbabwe** have **reached their 95-95-95 testing, treatment and viral load suppression targets.**

- Efforts in many countries to address HIV as part of a broader health and development agenda, encompassing maternal and child health, are **accelerating progress toward triple elimination of HIV, hepatitis B and syphilis.** Since 2015, **17 countries** have reached one or more of the targets for elimination of mother-to-child transmission of syphilis and/or HIV.

- Fewer people dying from AIDS-related causes means fewer children are left orphaned by the disease. **In countries where the Global Fund invests, the number of children orphaned by AIDS decreased by 26% between 2010 and 2023.**

HIV: State of the Fight

Fighting HIV contributes to strengthening health and community systems

Our investments in HIV up to the end of 2023 have freed up 1.66 billion hospitalization days that would have otherwise been used for HIV-related activities and averted 1.36 billion outpatient visits, generating US$85 billion in cost savings.

These gains are calculated by comparing the scale-up of key HIV services over the past two decades in Global Fund-supported countries with a counterfactual scenario assuming there was no scale up in HIV services in the same countries and years.

Number of HIV-related hospitalization days avoided

In countries where the Global Fund invests, 2002-2023



World Bank regions. This chart includes countries that received an allocation from the Global Fund since our inception up until December 2023.

The Global Fund/Quinn Ryan Mattingly

Tuberculosis

State of the Fight

In 2023, tuberculosis (TB) programs registered a complete recovery from the impact of the COVID-19 pandemic. However, TB continues to be fueled by inequity. We must accelerate the global TB response to get the world on track to end the disease by 2030.

Tuberculosis: State of the Fight

Trends in TB deaths (excluding HIV-positive)*

In countries where the Global Fund invests



Trends in new TB cases (all forms)

In countries where the Global Fund invests



*While major control efforts for malaria and HIV began with the launch of the Millennium Development Goals in 2000, TB control efforts began much earlier. The counterfactual and actual results therefore diverged from each other much earlier, making this graph look considerably different than its HIV and malaria counterparts.

The TB burden estimates are from the WHO Global Tuberculosis Report 2023. The estimation of "no TB control" trends for TB deaths from WHO and for new TB cases is based on the assumption of a constant trend in new TB cases since 2000.

Tuberculosis: State of the Fight

Key results for 2023 in countries where we invest

7.1 million People treated for TB*

TB treatment coverage



TB treatment success rate (all forms)



HIV+ TB patients on ARVs



*Programmatic results achieved during 2022 by countries and regions where the Global Fund invests. Progress graphs are based on latest published data from WHO (2022 release for TB and malaria) and UNAIDS (2023 release). Malaria mosquito net coverage calculated based on 38 African countries for which data is available from WHO/Malaria Atlas Project estimates.

Key Results

Tuberculosis: State of the Fight

In countries where the Global Fund invests:

7.1M

People were **treated for TB** in 2023.

121K

People were on **treatment for drug-resistant TB** in 2023; treatment coverage reached 33% in 2022 and the drug-resistant TB treatment success rate increased from 51% in 2010 to 70% in 2020. Global targets: 90% multidrug-resistant TB treatment coverage and success by 2025.

2M

People **exposed to TB received preventive therapy** in 2023.

70%

TB treatment coverage increased from 45% in 2010 to 70% in 2022, and the TB treatment success rate reached 88% in 2021. Global targets for coverage and treatment success rates: 90% by 2025.

353K

HIV-positive TB patients were on antiretroviral therapy during TB treatment in 2023; coverage of antiretroviral drugs in people with HIV and TB increased from 45% in 2010 to 91% in 2022. Global target: 100% among detected cases.

1.7M

People **living with HIV on antiretroviral therapy initiated TB preventive therapy** in 2023.

Tuberculosis: State of the Fight

Our progress

In countries where the Global Fund invests, TB deaths have declined by 36% between 2002 and 2022. Without these efforts, TB deaths would have increased by 129% and TB cases by 38% over the same period. The tuberculosis mortality rate has reduced by 54% since 2002, and the incidence rate declined by 28%.

- In 2023, Global Fund-supported TB programs recorded a complete recovery from COVID-19-related disruption to service delivery.
- The Global Fund is investing in innovative tools and novel approaches to find and treat the millions of “missing” people with TB, including mobile diagnostic units, AI-powered computer-aided detection software and digital chest X-rays.
- In 2023, efforts extended to address post-tuberculosis lung disease (PTLD). This hidden, negative after-effect of TB affects approximately 40% of individuals treated for and cured of TB. In collaboration with partners, **the Global Fund supported Kenya, Malawi, Tanzania and Uganda to integrate PTLD in national TB programs**.

The Global Fund/Andrew Esiebo/Panos.

Malaria

State of the Fight

In 2023, the Global Fund partnership accelerated the equitable deployment of tools for malaria prevention, testing and treatment and continued to build strong, climate-resilient health systems. The Global Fund partnership is fighting back to defeat this daunting global health challenge and build on the significant progress that we have made since 2002.

Malaria: State of the Fight

Trends in deaths and cases since 2002

Trends in malaria deaths

In countries where the Global Fund invests



Trends in malaria cases

In countries where the Global Fund invests



Malaria burden estimates and estimation of "no malaria control" from WHO World Malaria Report 2023.

Malaria burden estimates and estimation of "no malaria control" from WHO World Malaria Report 2023.

Malaria: State of the Fight

Key malaria results in 2023 in countries where we invest

227 million Mosquito nets distributed*

Mosquito nets population coverage



Mosquito nets population use



Suspected malaria cases tested



*Programmatic results achieved during 2022 by countries and regions where the Global Fund invests. Progress graphs are based on latest published data from WHO (2022 release for TB and malaria) and UNAIDS (2023 release). Malaria mosquito net coverage calculated based on 38 African countries for which data is available from WHO/Malaria Atlas Project estimates.

Key Results

Malaria: State of the Fight

In countries where the Global Fund invests:

227M

Mosquito nets were distributed to protect families from malaria in 2023.

171M

Cases of malaria were treated in 2023.

15.5M

Pregnant women received preventive treatment for malaria in 2023.

335M

Suspected cases of malaria were tested in 2023.

57%

Coverage of the **population with access to a long-lasting insecticide-treated net** increased from 30% in 2010 to 57% in 2022, and coverage of the population using a net increased from 26% in 2010 to 50% in 2022. Global target: Universal access to vector control for populations at risk.

7.9M

Structures were covered by indoor residual spraying in 2023.

44.6M

Children received **seasonal malaria chemoprevention** in 2023.

Malaria: State of the Fight

Our progress

- The Global Fund has been investing in the rollout and scale-up of game-changing dual active ingredient (dual AI) insecticide-treated nets in 2023. These nets combine two different classes of insecticides to ensure that mosquitoes resistant to one type are still killed by the second. These nets can **reduce malaria cases by an estimated 45% relative to other net types** and are critical to getting back on track in the fight against malaria.
- As a result of our collaboration and proactive engagement with in-country implementers, the rollout of these lifesaving new nets has already been much faster than anticipated. **Dual AI nets are expected to comprise 59% of insecticide-treated mosquito nets in the current grant cycle**.

- The Global Fund is supporting **malaria elimination efforts in 21 countries in Asia, Africa and Latin America**. In 2024 Cabo Verde was certified malaria-free by WHO, the latest on the list of 46 countries that have eliminated malaria since 2010.

Community health worker Lazare Kafando uses the mobile application Mhealth_Burkina to record and track patient data in Pousghin, Burkina Faso.

The Global Fund/Olympia de Maismont

Health and Community Systems

In 2023, the Global Fund accelerated investments to support countries to fight HIV, TB and malaria, strengthen health and community systems, and build pandemic preparedness.



The Global Fund/Brian Otieno

Health and Community Systems

In 2023, our core areas of investment in health and community systems focused on:

- Strengthening human resources for health.
- Strengthening health systems designed, led and organized by communities.
- Bolstering supply chains and using our market-shaping capabilities for better procurement and delivery of medicines and health products.
- Expanding and strengthening laboratory and diagnostics capacities.
- Expanding access to medical oxygen.
- Improving surveillance systems.
- Strengthening digital health and health information systems.

The Global Fund/TommyTrenchard/Rooftop

Health and Community Systems

Building pandemic preparedness

- Strong health systems are central to the fight against HIV, TB and malaria and to building pandemic preparedness and response.
- The Global Fund is working directly with countries to strengthen their capacities to prevent, prepare for and respond to existing and emerging infectious diseases, such as cholera, Ebola, and mpox.
- The Global Fund strategically adapted the focus of COVID-19 Response Mechanism (C19RM) funding to reflect countries' evolving priorities and to accelerate investments in health and community systems.

Reinvesting COVID-19 Response Mechanism (C19RM) funding

As the world has phased out of the emergency phase of the COVID-19 pandemic, the Global Fund has adapted to countries' evolving needs and made US$2.1 billion* of C19RM funding available to directly **strengthen health and community system**s and enhance **pandemic preparedness and response**.

We are reinvesting C19RM funding in five priority areas between 2021 and 2025**:**

- US$349 million in **human resources for health** in 95 countries.
- US$495 million in **laboratory systems** across 89 countries.
- US$441 million to support **health product and waste management systems**, including infection prevention and control.
- US$400 million in **surveillance systems strengthening** in 94 countries.
- US$564 million in **medical oxygen** across 83 countries.

*Based on signed budgets for 2024-2025 for C19RM, includes centrally managed limited investments (CMLIs) for the same period.

A recent analysis has shown that Global Fund oxygen investments in 14 priority countries are estimated to provide lifesaving oxygen access to around 22 million people between 2024 and 2026. These investments are expected to save around 520,000 lives and avert more than 2.8 million disability-adjusted life years (DALYs).



Procurement and Supply Chain Management

A key element of resilient and sustainable systems for health

---

The Global Fund is one of the world's largest brokers of medical supplies for low- and middle-income countries.

This allows us to deliver medicines and health products from manufacturers to the last mile.

We procure **US$2.5 billion** worth of health products each year. The larger share of those purchases goes through the Global Fund's Pooled Procurement Mechanism (PPM).

The Global Fund invested **US$202 million in 2023** to strengthen supply chain systems and accelerate the transition toward sustainability. We are investing US$308 million in this area in 2024.

In 2023, the Pooled Procurement Mechanism managed **US$1.34 billion** in orders across **81 countries**.

Market Shaping

In 2023, our market-shaping efforts resulted in significant price reductions for key commodities across the three diseases, enabling governments to expand interventions and invest in other critical areas.

HIV: Working with partners, we secured a **25% price reduction** for the preferred first-line HIV treatment.

TB: Working with partners, we were able to reduce prices by **20%** for diagnostic test cartridges for TB, by **30%** for the short course TB preventive treatment known as 3HP, and by **55%** for bedaquiline, the main treatment for drug-resistant TB.

Malaria: We also secured new dual active ingredient insecticide-treated nets, which are more effective against insecticide-resistant mosquitoes than conventional ones, at a **comparable price.**

By 2023, the Global Fund and partners had negotiated breakthrough antiretroviral medicine (ARV) pricing at under US$45 per person per year. In 2002 when the Global Fund started to finance ARVs, they had an annual per person cost of over US$10,000.

Progress toward UHC

- A new analysis shows that in the last two decades, **investments by the Global Fund partnership have significantly accelerated progress toward achieving UHC**. The global UHC service coverage index score increased from 45% in 2000 to 68% in 2021. This improvement is largely (61.2%) driven by the scale-up of antiretroviral therapy coverage. In addition, the scale-up of TB treatment and coverage of insecticide-treated nets were ranked as the 5th and 6th main drivers of this overall progress.

© UNICEF/UNI480811/Vignet

Colliding Crises

Multiple, interconnected and colliding crises affected our fight against HIV, TB and malaria in 2023. These include climate change, conflict and debt, as well as an alarming erosion of human rights. These crises made our efforts to get back on track against the three diseases much more challenging.

Colliding Crises
Breaking Down Barriers

Since 2017, our Breaking Down Barriers initiative has supported programs to remove human rights and gender-related barriers to services and to address stigma and discrimination in 24 countries.

We have increased our investments in this initiative by more than tenfold since 2017, reaching **over US$200 million** in 2023.

Progress assessments in 2023 found that the average score of human rights programming across Breaking Down Barriers countries had increased by 76% for HIV and 256% for TB from the baseline, demonstrating that our programs in these countries have been delivering impact.

Colliding Crises

Human rights and gender equality

Gender Equality Fund: In 2023 the Global Fund, ViiV Healthcare and GSK established a GBP 6 million fund to support women, girls, trans and gender-diverse people to meaningfully engage in decision-making spaces, tackle the root causes of gender inequality and strengthen locally led movements for gender equality.

HER Voice Fund: Since 2018, the Global Fund has invested in the HER Voice Fund**,** which supports the leadership of adolescent girls and young women in 13 priority countries in East and Southern Africa, providing small grants to help this group participate in advocacy and policy processes. In 2023, the HER Voice Fund reached over 68,000 adolescent girls and young women.

Voix EssentiELLES: In francophone West and Central Africa, the Global Fund supports the civil society-led fund Voix EssentiELLES to strengthen women and girls' engagement in Global Fund-related processes and national health policies. In 2023, this fund supported 40 women and girls' organizations based in Burkina Faso, Côte d'Ivoire and Senegal.

Colliding Crises

Conflict and humanitarian crises

The Global Fund seeks to safeguard the gains made against HIV, TB and malaria in countries affected by conflict, while building strong health and community systems.

The Global Fund prioritizes health needs in countries affected by humanitarian crises, which account for approximately **one-third of the global disease burden** for HIV, TB and malaria and **over 34% of the Global Fund's funding allocation** over the next three years.

We have disbursed **US$22 billion** to countries affected by humanitarian crises since 2002.

Even in crisis, we must leave no one behind. We adapt our model and provide speedier responses, recognizing the need to adapt approaches to each context while maintaining responsible fiduciary oversight of funds and reducing the administrative burden for partners.

Colliding Crises
The Emergency Fund

Established in 2014, the Emergency Fund provides quick and flexible financing in emergencies to ensure the continuity of existing HIV, TB and malaria programs and services.

From 2014 to 2023, support has mainly addressed emergencies triggered by conflict and climate-related disasters, followed by support to address the needs of displaced populations.

The Global Fund has approved over US$130 million through the Emergency Fund in the last 10 years.



Colliding Crises

Climate change adaptation

The Global Fund supports countries with climate adaptation, investing in activities designed to embed climate resilience in health and community systems and climate-proof health facilities and infrastructure.

Our investments support:

- Disaster risk management for health.
- Vulnerability, risk and impact assessments and planning.
- Disease surveillance and early warning systems.
- Climate-sensitive disease control in vulnerable areas.

We are supporting **Mozambique** to develop a new Health National Adaptation Plan, promoting climate resilience and environmental safeguards for health facilities and storage.

In the **Lao People's Democratic Republic** and **South Sudan**, the Global Fund, the World Bank and other financing partners are collectively investing in climate adaptation measures for resilient health facilities and service delivery in climate disaster-prone areas.

Colliding Crises

Climate change mitigation

The Global Fund invests in building efficient and clean energy solutions in the health sector. We also support the streamlining of supply chains to reduce carbon emissions and lessen the environmental consequences of our partnership's investments.

We are investing vigorously in **solar projects**: In the last seven years, we have supported the **solarization of more than 1,000 health centers and storage facilities in 15 African countries**, including in Zambia and Zimbabwe.

In our grants covering 2024-2026, over 20 countries have included the installation of solar panels on health or storage facilities in their funding requests.

We are also exploring ways to reduce the carbon emissions across the value stream of health products, such as mosquito nets, and through the Responsible Procurement Framework.

UNDP/Karin Schermbrucker

© UNICEF/UNI560974/Bak Mejlvang

Investing for Impact

The Global Fund unites the world to save lives, defeat HIV, TB and malaria, and build a healthier, safer, more equitable future for all. We bring together world leaders, communities, civil society, health workers and the private sector to find solutions that have the most impact, and we take them to scale worldwide. We disbursed US$5 billion in 2023 to fight deadly infectious diseases, challenge the inequity that fuels them and strengthen health systems in more than 100 countries.

Investing for Impact

Where our investments come from

Since 2002, we have disbursed more than **US$65.4 billion** to respond to HIV, TB and malaria and to strengthen systems for health across **more than 100 countries**.

In 2023, the Global Fund disbursed **US$5 billion** – the third year in a row of record investments since our founding.

Public donors are the primary source of funding for the Global Fund.

Private sector and nongovernment partners are expanding the reach of our investments to increase our impact in specific priority areas.

Domestic financing plays a critical role in achieving sustainable impact. The Global Fund continues to play a strong role in advocating for and catalyzing domestic investments in health.

To encourage the sustainability of country-level disease programs, the Global Fund helps countries choose activities that balance impact and cost.



Investing for Impact

Global Fund investments by region in 2021-2024 as of June 2024



The sum of percentages across regions does not add up to 100% due to rounding.

Investing for Impact

Where does our funding go?

Disbursements for HIV, TB and malaria grants and COVID-19 Response Mechanism funding



The sum of the values does not add up to 100% due to rounding. Data for Grant Cycle 6 is as of 30 June 2024.

Investing for Impact

International grants provided by the Global Fund in 2023



28%

of all international financing for **HIV**

76%

of all international financing for **TB**

62%

of all international financing for **malaria**

This data is provided by UNAIDS (for HIV) and the World Health Organization (for TB and malaria).

Results Report suite of assets

- **Results Report in English**
- **At a Glance in 10 languages:** English, French, Arabic, German, Italian, Japanese, Korean, Portuguese, Spanish, Chinese
- **Interactive webpage:** charts with country data, drop down menu function, methodology
- **Social media toolkit:** available at the same time as the report launch. It will include data graphics, case studies, title cards, and social media messages. It will be available in EN and FR.
- **Social media tiles**
- **Results Report video/reel**
- **News release**
- **Op-Ed by Peter Sands on Forbes**
- **Results Report slide deck**
- *Results Report in FR and slide deck in FR available later in October*

THE GLOBAL FUND

The Global Fund to Fight
AIDS, Tuberculosis and Malaria

Global Health Campus
Chemin du Pommier 40
1218 Le Grand-Saconnex
Geneva, Switzerland
+41 58 791 17 00
theglobalfund.org